IHH Healthcare

IHH Healthcare: UOB Kay Hian note that 1H13 earnings rose 29% y/y and represents 44% of consensus estimates. Near-term risks are amplified on the back of the uncertain macroeconomic picture. Execution of its pipeline poses key challenges for the group. Currency volatility could impact bottom-line. Overall, house maintains SELL with a revised target price of $1.43.